Cargando empresa
Just reported
Q3 2026 results
From Neuropace's results release of 12 de noviembre de 2026. These are the company's first figures; its 10-Q or 10-K replaces them when filed.
Revenue
Actual
23,1M US$
-16 % y/y
+1,2 % q/qGuided
—
No guide given
Operating income, adjusted
Actual
400K US$
Guided
—
No guide given
Company outlook
Full year 2026
- Revenue91M US$ – 92M US$-8,5 % y/y Lowered -9,0 %
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →Keep exploring
The themes Neuropace is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Medical Devices
Graded A or B and worth $2B or more: A first, then the largest.
MDTMedtronic plc131,6B US$A+
SYKStryker Corp.117,9B US$A+
EWEdwards Lifesciences Corporation61,6B US$A+
GEHCGE Healthcare Technologies Inc.37,5B US$A
GKOSGlaukos Corp14,5B US$A
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 oct 2026CBGraded C, now B
MCKMckesson Corporation4 nov 2026BAGraded B, now A
CVSCVS Health Corp4 nov 2026BAGraded B, now A- EWEdwards Lifesciences Corporation4 nov 2026BAGraded B, now A
- GEHCGE Healthcare Technologies Inc.28 oct 2026CAGraded C, now A
Estados financieros completos →
Construido a partir de los propios informes de Neuropace, Inc. ante la Comisión de Bolsa y Valores de EE. UU. (SEC). Las cifras son las declaradas, con el historial por acción reexpresado a la base de acciones de hoy. Esto describe un negocio: no es asesoramiento de inversión ni una recomendación de compra o venta.
